leisure time -WSS

leisure time

author：knowledge 2025-09-03 15:21:18 - browse：3

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： 2 million sign

focus

WSS

Princess Kate attends Wimbledon with Roger Federer: See the photos

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

STAT reporters are Pulitzer Prize finalists for investigative reporting

EU moves toward latest gene techniques in food production to counter climate change, shortages

Pentagon will tighten controls on classified information after Discord leak

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

leisure time

leisure time

focus

Psychedelics group wrestles with new pharma identity

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Activists slam private health insurers over coverage restrictions

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

As H5N1 spreads in cows, experts warn against drinking raw milk

Heart attack and stroke risk calculators need revising

The leaders of Italy and Poland say European Union should focus on stopping migration

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The leaders of Italy and Poland say European Union should focus on stopping migration

explore

ALS treatment from Biogen, Ionis fails in study

Condition critical? Britain's beloved but battered National Health Service turns 75

Free medical tuition alone isn't enough to close gaps in primary care

Condition critical? Britain's beloved but battered National Health Service turns 75

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

explore

focus

entertainment

knowledge